Dimensional Fund Advisors LP Acquires 4,145 Shares of United Therapeutics Corporation $UTHR

Key Points

• Dimensional Fund Advisors LP increased its stake in United Therapeutics Corporation by 0.7%, owning 624,711 shares valued at approximately $192.57 million as of its latest SEC filing.
• Institutional investors now hold a significant 94.08% of United Therapeutics' stock, with various firms including Raymond James Financial and NewEdge Advisors recently adjusting their positions.
• United Therapeutics reported $6.41 earnings per share, missing the analysts' consensus estimate, while revenues grew by 11.7% year-over-year despite missing the consensus revenue target.

Dimensional Fund Advisors LP raised its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 0.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 624,711 shares of the biotechnology company's stock after acquiring an additional 4,145 shares during the quarter. Dimensional Fund Advisors LP owned about 1.38% of United Therapeutics worth $192,571,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. XTX Topco Ltd bought a new stake in shares of United Therapeutics during the first quarter valued at approximately $313,000. Allianz Asset Management GmbH boosted its position in United Therapeutics by 96.9% in the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock valued at $20,832,000 after buying an additional 33,254 shares during the last quarter. LPL Financial LLC increased its stake in shares of United Therapeutics by 77.3% in the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock valued at $7,783,000 after buying an additional 11,007 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of United Therapeutics by 11.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock worth $1,129,000 after acquiring an additional 376 shares during the last quarter. Finally, Concurrent Investment Advisors LLC bought a new stake in shares of United Therapeutics during the first quarter worth $227,000. 94.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. HC Wainwright set a $400.00 price objective on United Therapeutics and gave the stock a "buy" rating in a research report on Thursday, July 31st. Wells Fargo & Company reduced their target price on shares of United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 31st. Bank of America dropped their price target on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday, June 11th. JPMorgan Chase & Co. cut their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday, July 8th. Finally, Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $382.00.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 12,000 shares of the company's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the transaction, the chief financial officer directly owned 8,118 shares of the company's stock, valued at $2,641,353.66. This represents a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $308.75, for a total value of $3,396,250.00. Following the transaction, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $11,356,133.75. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 92,681 shares of company stock valued at $28,014,609. 10.30% of the stock is owned by insiders.

United Therapeutics Stock Performance

NASDAQ:UTHR traded up $1.57 on Friday, reaching $312.23. The company's stock had a trading volume of 576,473 shares, compared to its average volume of 525,026. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $417.82. The business's 50-day moving average price is $296.44 and its two-hundred day moving average price is $307.95. The firm has a market cap of $14.08 billion, a PE ratio of 12.19, a PEG ratio of 4.64 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). The business had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company's revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter last year, the firm earned $5.85 EPS. As a group, sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.